Skip to main content
CING
NASDAQ Life Sciences

Cingulate Inc. Corrects Proxy Statement, Disclosing New 18.16% Beneficial Owner

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$8.11
Mkt Cap
$87.947M
52W Low
$3.2
52W High
$11.89
52W Position info
153% above low
Off High info
32% below high
Rel. Volume info
5.6× avg
Market data snapshot near publication time

CING has more than doubled off its 52-week low of $3.2 on elevated volume (5.6× avg).

Summary

Cingulate Inc. filed a DEFA14A to correct an administrative error in its proxy statement, disclosing Falcon Creek Capital Advisor LLC as an 18.16% beneficial owner.


Key Events · Corporate Governance and Compliance · CING

  • Material Ownership Disclosure Corrected

    The company filed a DEFA14A to amend its definitive proxy statement, correcting an administrative error in the 'Security Ownership of Certain Beneficial Owners and Management' section.

  • Falcon Creek Capital Advisor LLC Revealed as Major Shareholder

    The amendment discloses Falcon Creek Capital Advisor LLC as a beneficial owner of 1,951,946 shares, representing 18.16% of the company's outstanding common stock as of February 13, 2026. This significant stake was previously omitted.


Analysis · CING · Life Sciences

This DEFA14A filing corrects a material administrative error in the previously filed definitive proxy statement. It reveals that Falcon Creek Capital Advisor LLC holds an 18.16% beneficial ownership stake in Cingulate Inc., an omission that significantly impacted the transparency of the company's ownership structure. This disclosure is particularly relevant given the company's recent 10-K filing, which included a going concern warning and highlighted a short cash runway. Understanding the full ownership landscape is crucial for investors assessing the company's strategic direction and potential future financing, especially when the company faces significant operational and financial challenges.

At the time of this filing, CING was trading at $8.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87.9M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CING - Latest Insights

CING
Jul 02, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $4.45 info
Change: -$1.45 (-25%) info
Market Cap: $61.015M info
CING
Jun 16, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.87
Real-time Price: $4.45 info
Change: -$0.416 (-9%) info
Market Cap: $61.015M info
CING
Jun 02, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.79
Real-time Price: $4.45 info
Change: +$0.660 (+17%) info
Market Cap: $61.015M info
CING
Jun 02, 2026, 8:05 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $3.79
Real-time Price: $4.45 info
Change: +$0.660 (+17%) info
Market Cap: $61.015M info
CING
May 29, 2026, 9:16 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $4.30
Real-time Price: $4.45 info
Change: +$0.150 (+3%) info
Market Cap: $61.015M info